The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Froriep

4 RUE CHARLES-BONNET, CASE POSTALE 399, 1211 GENÈVE 12, SWITZERLAND
Tel:
Work +41 22 839 63 00
Fax:
Fax +41 22 347 71 59
Email:
Web:
www.froriep.com
Geneva, London, Madrid, Zug, Zurich

Jérôme de Montmollin

Tel:
Work +41 22 839 63 00
Email:
Web:
www.froriep.com
Froriep

Work Department

Corporate / Commercial, Banking / Finance, M&A, Insolvency.

Position

Jérôme is an experienced corporate and commercial lawyer with expertise in the oil and gas industry, in debt collection and in bankruptcy matters.

Career

Jérôme has been a partner at Froriep's Geneva office since 1998, after having been an associate in our Geneva and London offices from 1989. He is experienced in finance transactions, mainly in the field of oil and gas, and in corporate and commercial law, including mergers and acquisitions. He also has wide experience in debt collection and bankruptcy matters, as well as assets tracing, including civil and criminal attachments. Before joining Froriep, he worked for five years as a clerk with the Swiss Supreme Court (civil court and debt collection and bankruptcy court).

Languages

Jérôme working languages are French, English, Italian and German.

Member

Jérôme is a member of the Geneva Bar Association, the Swiss Bar Association and Union Internationale des Avocats (UIA).

Education

Jérôme obtained his law degree from the University of Neuchâtel in 1980 and was admitted to the Bar in 1983.


Switzerland

Banking and finance: Geneva

Within: Banking and finance: Geneva

Froriep's practice is best known for its banking M&A, regulatory and international financing expertise. Jean-Luc Herbez assisted investment vehicle JFK Capital Alternative Sicav with obtaining a Swiss collective investment scheme licence from FINMA. Transaction partner JérÎme de Montmollin, Russian/CIS desk lead Dmitry Pentsov and investment product specialist Laetitia Meier Droz, who became a partner in January 2018, make up the core team.

[back to top]

Commercial, corporate and M&A

Within: Commercial, corporate and M&A

'A reliable international partner', Froriep's 'pleasant team' serves as 'a one-stop shop' due to its 'flexible approach' and 'technical capability'. Private M&A and corporate transactions, especially up to mid-market value, are a particular focus of the department, alongside investment rounds for start-ups and the real estate sector. Catrina Luchsinger advised Palmarium Group and its Dutch subsidiary Vieo on the bond-issue acquisition of all shares in Lebara Group, while the 'responsive and trustworthy' Mattias Johnson assisted Envican with its corporate reorganisation, its first financing round and entering into a strategic partnership. Clients further recommend 'organised and knowledgeable' Dmitry Pentsov, who specialises in corporate transactions involving Russian companies, commercial partner JérÎme de Montmollin , who provides 'clear' advice', and 'very good' B-corporations expert Julie Wynne.

[back to top]

Leading firms: French-speaking Switzerland

Within: Leading firms: French-speaking Switzerland

Froriep's Geneva-based team covers banking, corporate, sports and private client law. Jean-Luc Herbez, JérÎme de Montmollin, Jean Marguerat, Julie Wynne and Dmitry Pentsov are well-known partners.

[back to top]


Back to index

Legal Developments by:
Froriep

Legal Developments in Switzerland

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • BĂ€r & Karrer Awarded "Law Firm of the Year - Switzerland" at the Citywealth Magic Circle Awards 201

    BĂ€r & Karrer is pleased to announce that it has received the award “Law Firm of the Year - Switzerland” at the Citywealth Magic Circle Awards in London. This award recognizes BĂ€r & Karrer as the Swiss law firm with the best private client team.
  • BĂ€r & Karrer Advises Ashcroft on the Acquisition of RĂŒeger Holding

    Ashcroft Inc., headquartered in Stratford, CT, USA, a subsidiary of Tokyo Stock Exchange listed Nagano Keiki Co., Ltd, has announced the completion of the acquisition of Swiss-based RĂŒeger Holding SA (RĂŒeger) and Dutch-based STIKO Meetapparentenfabriek B.V. (Stiko), both manufacturers of specialty temperature and pressure measurement products, from their previous owners, Bernard and Jean-Marc RĂŒeger.
  • Ordinance on Integrity and Transparency in the Therapeutic Products Sector has been adopted

    Click here for more information.
  • BĂ€r & Karrer Advises B3i in its Current Equity Funding Round

    Industry-led InsurTech B3i Services AG successfully raised additional funds from current shareholders and new investors to further develop and grow its blockchain-based insurance transaction platform. B3i was founded in October 2016 as an insurance industry consortium which then formed B3i Services AG as an independent company. The shareholder group includes some of the world's largest insurers and reinsurers from across Europe, the Americas, and Asia. B3i intends to further expand its shareholder base over the next several months.
  • BĂ€r & Karrer Continues to Grow Finance and Sports Practice with Two New Partners

    BĂ€r & Karrer is pleased to announce that it further strengthens its Financing and Sports practices with new partners Lukas Roesler and Dr. Jan Kleiner, both of whom have worked with the firm previously.
  • BĂ€r & Karrer Advises Novartis and Alcon on the Spin-off of Alcon

    Today, Novartis AG completed the spin-off of the Alcon eye care devices business, and Alcon Inc. debuted as independent publicly traded company. The Alcon shares were successfully listed on the SIX Swiss Exchange Ltd. and the New York Stock Exchange. They are also included in the Swiss Market Index (SMI), which comprises the 20 largest Swiss listed stocks.
  • BĂ€r & Karrer Advises Primeo Energie and CSA Energie-Infrastructure Schweiz in Aquisition from ElĂ©t

    Primeo Energie, EOS Holding SA (EOS) and ÉlectricitĂ© de France (EDF) have entered into a share purchase agreement relating to the purchase by Primeo Energie and EOS of the 25% interest held by EDF in Alpiq Holding SA. The purchase by Primeo Eergie and EOS will be financed through mandatory exchangeable loan agreements made by CSA Energie-Infrastruktur Schweiz (CSA) as lender, the biggest investment pool for Swiss energy infrastructure with 135 Swiss pension funds acting as investors. At maturity the mandatory exchangeable loan agreements will be converted into shares in Alpiq. Primeo Energie and EOS thereby pave the way for a Swiss shareholder structure of Alpiq.
  • BĂ€r & Karrer Awarded Most Innovative Swiss Law Firm of the Year at the IFLR Europe Awards

    BĂ€r & Karrer was awarded „Most innovative law firm of the year - Switzerland", the national award for Switzerland given in the IFLR European Awards. The most innovative law firm of the year award recognizes BĂ€r & Karrer as the Swiss law firm with the best track record in 2018 giving advice on the most innovative cross-border deals covering all award practice areas. It is already the third prize of this kind in period of six years awarded to BĂ€r & Karrer.
  • BĂ€r & Karrer Advises DSV on Public Exchange Offer for Panalpina

    On 1 April 2019, DSV A/S, Hedehusene, Denmark and Panalpina Welttransport (Holding) AG, Zurich, Switzerland, have entered into an agreement on the terms and conditions of a combination by way of a public exchange offer by DSV for all publicly held registered shares of Panalpina for approximately CHF 4.6 billion. The board of directors of Panalpina has resolved to support the public exchange offer by DSV and to recommend the acceptance of DSV's public exchange offer to its shareholders.
  • BĂ€r & Karrer Advises Lonza on the Entering into a Strategic Joint Venture with Chr. Hansen for Deve

    On 2 April 2019, Lonza, a leading pharma contract manufacturing company, and Chr. Hansen, a leading global bioscience company, announced that they have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture brings together best-in-class, complementary capabilities and will be the first CDMO globally to provide a full supply chain that offers manufacturing of bacteria strains for therapeutic use. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel (CH) and have production facilities in Denmark and Switzerland. A phased investment of approximately EUR 90 million will be deployed over three years to build cGMP-compliant pharma production capabilities. The joint venture will upgrade existing facilities in HÞrsholm (DK) and equip new facilities in Basel (CH) to serve pre-clinical to phase II projects. Further facilities for phase III and commercial manufacturing will be developed as the pipeline matures. The joint venture is expected to be largely self-funding after the production set-up has been established.